Trividia Health Inc. announced the acquisition of certain assets from Freedom Meditech, and the creation of Sinocare Meditech.
Freedom Meditech has developed an FDA cleared noninvasive six second eye scan that utilizes lens autoflourescence to detect the presence of advanced glycation products or AGEs in the lens of the eye. This technology has the potential application to screen for chronic diseases such as diabetes.
In the USA alone, the number of diabetics is an estimated 21 million people with a financial impact of 245 billion dollars in healthcare costs.
According to the American Diabetes Association, 8.1 million patients in the USA remain undiagnosed representing 18 billion dollars in future healthcare costs. Through screening and early diagnosis, healthcare professionals and patients can improve outcomes and lower costs to the healthcare system.
Trividia Health will continue to develop this new technology and expand clinical evaluation with the goal of marketing the next generation device in the over 48,000 pharmacies in the USA that co-brand our Diabetes Management products. “Our retail partners are committed to early intervention and making community pharmacies the focal point for care. As the number of in-store clinics continues to grow and the number of screenings continues to expand, this technology will fill the void. We will work with our customers, payors and providers on the best implementation strategy,” said Scott Verner, President and CEO of Trividia Health.